Skip to content

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Obinutuzumab β for aquaporin-4-positive neuromyelitis optica spectrum disorder: a phase 3 randomized controlled trial.

Although CD20-directed B cell depletion has long been used in neuromyelitis optica spectrum disorder (NMOSD), high-quality, large-scale, randomized controlled trials remain limited. In this multicenter, randomized, double-blind phase 3 trial, we evaluated obinutuzumab β (MIL62), a novel glycoengineered type II anti-CD2...

Lei Wu, Liangliang Gu, Wei-Hao Fan et al. · 1 citation
Open access Sep 2026

Complement C5 inhibitor as a rescue therapy for acute NMOSD attacks: a multicenter retrospective cohort study in China

Background Complement activation plays a key role in the pathogenesis of neuromyelitis optica spectrum disorder (NMOSD). While eculizumab effectively prevents relapses, its role in acute attacks remains uncertain. Methods We retrospectively analyzed 38 patients with acute NMOSD treated with eculizumab across seven tert...

Tao Wu, De-Cai Tian, De-Hui Huang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.